On the other hand, IGF2BP1/2/3 stabilize specific m6A-modified mRNA, enabling fine-tuned regulation of immune-related gene expression, which in turn indirectly affects the overall outcome of liver cancer immunotherapy (14). Here, IGF2BP1 is linked to liver cancer.